Trials that use: Log-rank test
New to this method? Read the tutorial →
220 results
- ABCSG-16Complete statistical analysis of ABCSG-16, the randomized phase 3 trial comparing 2 versus 5 years of additional anastrozole after 5 years of adjuvant endocrine therapy in breast cancer, including time-to-event endpoints, hazard…
- ACTG A5279Independent statistical analysis of ACTG A5279 (NCT01404312), a randomized phase 3 trial comparing a rifapentine-plus-isoniazid regimen with an isoniazid regimen for tuberculosis prevention in people with HIV.
- ACTT-2Independent statistical analysis of ACTT-2, the randomized phase 3 trial of remdesivir plus baricitinib versus remdesivir plus placebo in COVID-19, including time-to-recovery, ordinal-scale, and safety analyses.
- ACTT-3Independent statistical analysis of ACTT-3, the phase 3 randomized trial of remdesivir plus interferon beta-1a versus remdesivir plus placebo in COVID-19, including time-to-recovery, subgroup hazard ratios, safety, and statistical interpretation.
- ADAURAIndependent statistical analysis of the ADAURA phase 3 trial of AZD9291 versus placebo after complete tumour resection in stage IB-IIIA non-small cell lung carcinoma, including disease-free survival, overall survival, trial design, methodology,…
- ADRIATICIndependent statistical analysis of the phase 3 ADRIATIC trial of durvalumab, tremelimumab, and placebo in limited-stage small-cell lung cancer after concurrent chemoradiation, including randomized design, time-to-event endpoints, hazard ratios, confidence intervals, and…
- AFFIRMComplete statistical analysis of the AFFIRM phase 3 trial of enzalutamide versus placebo in patients with castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy, including overall survival, secondary time-to-event endpoints, response measures,…
- AGO-OVAR 12Independent statistical analysis of AGO-OVAR 12 (NCT01015118), a randomized phase 3 trial of nintedanib or placebo with paclitaxel and carboplatin in first-line ovarian cancer, including progression-free survival, overall survival, response, quality of…
- ALEXIndependent statistical analysis of the phase 3 ALEX trial comparing alectinib with crizotinib in treatment-naive ALK-positive advanced non-small cell lung cancer, including progression-free survival, CNS progression, overall survival, response, quality-of-life endpoints, and…
- ALLIANCE A041202Independent statistical analysis of ALLIANCE A041202, a randomized phase 3 trial comparing rituximab and bendamustine hydrochloride, ibrutinib, or ibrutinib plus rituximab in older patients with previously untreated chronic lymphocytic leukemia.
- ALTTOIndependent statistical analysis of the phase 3 ALTTO trial of lapatinib and trastuzumab in breast neoplasms, covering randomized trial design, disease-free survival, overall survival, recurrence endpoints, safety, and time-to-event methodology.
- APACTIndependent statistical analysis of APACT, the randomized phase 3 trial of nab-paclitaxel and gemcitabine versus gemcitabine alone as adjuvant therapy for patients with resected pancreatic cancer.
- APHINITYAn independent statistical analysis of APHINITY, the randomized phase 3 trial of pertuzumab added to trastuzumab and chemotherapy as adjuvant therapy in participants with HER2-positive primary breast cancer.
- ARAMISIndependent statistical analysis of the phase 3 ARAMIS trial of darolutamide versus placebo in men with high-risk non-metastatic castration-resistant prostate cancer, including metastasis-free survival, overall survival, time-to-event methods, and statistical interpretation.
- ARASENSIndependent statistical analysis of ARASENS, the randomized phase 3 trial of darolutamide plus standard androgen deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer, including time-to-event methodology, reported hazard ratios, confidence intervals,…
- ARCHER 1050Independent statistical analysis of ARCHER 1050, the randomized phase 3 trial of dacomitinib versus gefitinib in first-line advanced NSCLC with EGFR-activating mutations, including PFS, overall survival, response, statistical methodology, and interpretation.
- ARCHESComplete statistical analysis of the ARCHES phase 3 trial of enzalutamide plus androgen deprivation therapy versus placebo plus ADT in metastatic hormone sensitive prostate cancer, including rPFS, overall survival, secondary endpoints, statistical…
- ARTEMIS-IPFIndependent statistical analysis of ARTEMIS-IPF, the randomized phase 3 trial of ambrisentan versus placebo in idiopathic pulmonary fibrosis, including its time-to-event endpoint, hazard ratio, secondary analyses, statistical methods, and interpretation.
- ASCENTIndependent statistical analysis of ASCENT, a randomized phase 3 trial of sacituzumab govitecan versus Treatment of Physician's Choice in participants with refractory or relapsed metastatic triple-negative breast cancer.
- ATLASIndependent statistical analysis of the ATLAS phase 3 trial comparing bevacizumab plus erlotinib with bevacizumab plus placebo for first-line treatment of non-small cell lung cancer, including progression-free survival, overall survival, trial design,…
- AUGMENTIndependent statistical analysis of the phase 3 AUGMENT trial of rituximab plus lenalidomide versus rituximab plus placebo in relapsed or refractory indolent non-Hodgkin's lymphoma, including progression-free survival, overall survival, response endpoints, statistical…
- AURA3Complete statistical analysis of AURA3, the randomized phase 3 trial of osimertinib versus platinum-based doublet chemotherapy in locally advanced or metastatic non-small cell lung cancer, including endpoints, statistical methods, efficacy results, safety,…
- AURELIAIndependent statistical analysis of AURELIA, the randomized phase 3 trial of bevacizumab added to chemotherapy in patients with platinum-resistant ovarian cancer, including progression-free survival, response, overall survival, quality of life, statistical methodology,…
- AVERROESComplete statistical analysis of AVERROES, the randomized phase 3 study of apixaban versus acetylsalicylic acid in patients with atrial fibrillation, including trial design, time-to-event endpoints, hazard ratios, confidence intervals, safety, and statistical…
- AXISIndependent statistical analysis of the phase 3 AXIS trial of axitinib versus sorafenib in metastatic renal cell cancer, including progression-free survival, overall survival, objective response rate, statistical methods, and interpretation.
- BARI 2DIndependent statistical analysis of BARI 2D, a randomized phase 3 factorial trial comparing revascularization with medical therapy and insulin-sensitizing with insulin-providing glycemic strategies, including five-year all-cause mortality and death, myocardial infarction, or…
- BELLE-2Independent statistical analysis of the BELLE-2 phase 3 trial of BKM120 plus fulvestrant versus placebo plus fulvestrant in postmenopausal patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer refractory to…
- BELLE-3Independent statistical analysis of BELLE-3, a randomized phase 3 study of BKM120 with fulvestrant versus placebo with fulvestrant in patients with HR+, HER2-, AI-treated locally advanced or metastatic breast cancer who progressed…
- BOLERO-2Independent statistical analysis of BOLERO-2 (NCT00863655), a randomized phase 3 trial of everolimus plus exemestane versus placebo plus exemestane in postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer…
- BOLERO-3Independent statistical analysis of BOLERO-3, a randomized phase 3 trial of everolimus plus trastuzumab and vinorelbine versus placebo plus trastuzumab and vinorelbine in HER2/Neu-positive locally advanced or metastatic breast cancer.
- BREAKWATERIndependent statistical analysis of the BREAKWATER phase 3 trial of encorafenib plus cetuximab with or without chemotherapy in previously untreated metastatic colorectal cancer, including trial design, primary endpoints, hazard ratios, odds ratios,…
- BRIM-3Independent statistical analysis of the randomized phase 3 BRIM-3 trial of vemurafenib versus dacarbazine in previously untreated patients with metastatic melanoma, including time-to-event endpoints, hazard ratios, confidence intervals, log-rank testing, and interpretation.
- CALLAIndependent statistical analysis of the CALLA phase 3 trial of durvalumab with chemoradiotherapy in women with locally advanced cervical cancer, including trial design, progression-free survival, overall survival, response endpoints, safety, and statistical…
- CASPIANIndependent statistical analysis of CASPIAN, the randomized phase 3 trial of durvalumab with platinum-based chemotherapy in untreated extensive-stage small cell lung cancer, including overall survival, progression-free survival, response, statistical methodology, and interpretation.
- CASSIOPEIAA complete statistical analysis of the phase 3 CASSIOPEIA trial evaluating daratumumab in transplant-eligible participants with previously untreated multiple myeloma, including trial design, primary endpoints, reported statistical analyses, safety, and interpretation.
- CELESTIALIndependent statistical analysis of the phase 3 CELESTIAL trial of cabozantinib versus placebo in hepatocellular carcinoma after prior sorafenib, including overall survival, progression-free survival, objective response, trial design, and statistical methodology.
- CheckMate-026Independent statistical analysis of CheckMate-026, a randomized phase 3 trial of nivolumab versus investigator's choice chemotherapy as first-line therapy for stage IV or recurrent PD-L1+ non-small cell lung cancer.
- CheckMate-057Independent statistical analysis of CheckMate-057, a randomized phase 3 trial comparing nivolumab with docetaxel in previously treated metastatic non-squamous non-small cell lung cancer, including overall survival, hazard ratio, log-rank testing, and interpretation.
- CheckMate-078Independent statistical analysis of CheckMate-078, a randomized phase 3 trial comparing nivolumab with docetaxel in previously treated advanced or metastatic non-small cell lung cancer.
- CheckMate-141Independent statistical analysis of CheckMate-141, the randomized phase 3 trial of nivolumab versus investigator's choice therapy in recurrent or metastatic squamous cell carcinoma of the head and neck.
- CheckMate-238Independent statistical analysis of CheckMate-238, a randomized phase 3 trial of nivolumab versus ipilimumab for prevention of melanoma recurrence after complete resection of stage IIIb/c or stage IV melanoma.
- CheckMate-459Independent statistical analysis of CheckMate-459, a randomized phase 3 trial comparing nivolumab with sorafenib as first treatment in advanced hepatocellular carcinoma, including overall survival, response, progression-free survival, statistical methods, and interpretation.
- CheckMate-649Independent statistical analysis of CheckMate-649, a randomized phase 3 trial of nivolumab plus chemotherapy versus chemotherapy in stomach cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, focusing on overall survival, progression-free survival, hazard…
- CheckMate-651Independent statistical analysis of CheckMate-651, a randomized phase 3 trial of nivolumab plus ipilimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and…
- CheckMate-816Independent statistical analysis of CheckMate-816, a randomized phase 3 trial of nivolumab plus platinum-doublet chemotherapy versus chemotherapy alone in early-stage non-small cell lung cancer.
- CheckMate-914Independent statistical analysis of CheckMate-914, a randomized phase 3 trial of nivolumab, nivolumab plus ipilimumab, and placebo in participants with localized renal cell carcinoma after surgery.
- CIRTComplete statistical analysis of CIRT (NCT01594333), a randomized phase 3 trial of methotrexate versus placebo in cardiovascular disease, including time-to-event endpoints, hazard ratios, confidence intervals, log-rank testing, stratification, multiplicity, safety, and statistical…
- CLEAR OutcomesIndependent statistical analysis of CLEAR Outcomes, the randomized phase 3 trial of bempedoic acid versus placebo in statin-intolerant participants with or at high risk for cardiovascular disease, including MACE, secondary time-to-event endpoints,…
- CLEOPATRAIndependent statistical analysis of CLEOPATRA, the randomized phase 3 trial of pertuzumab plus trastuzumab and docetaxel versus placebo plus trastuzumab and docetaxel in previously untreated HER2-positive metastatic breast cancer.
- CLL14Independent statistical analysis of the CLL14 phase 3 trial comparing obinutuzumab plus venetoclax with obinutuzumab plus chlorambucil in chronic lymphocytic leukemia, including time-to-event and response analyses.